CAR-MSCs Emerge as a Powerful Next-Generation Cell Therapy Platform
Engineered mesenchymal stem cells carrying CAR molecules combine precision tumor targeting with innate immunomodulation, opening new frontiers in cancer and immune disease therapy.
Summary
Researchers have comprehensively reviewed CAR-MSCs — mesenchymal stem cells engineered with chimeric antigen receptors — as a promising evolution beyond CAR-T cell therapy. While CAR-T cells have transformed blood cancer treatment, they face persistent challenges including toxicity, poor solid tumor penetration, and limited durability. CAR-MSCs leverage MSCs' natural tumor-homing ability, low immunogenicity, and immunomodulatory properties, pairing these with CAR-directed antigen targeting. Preclinical studies demonstrate efficacy against glioblastoma, Ewing sarcoma, acute myeloid leukemia, and lung cancer, as well as graft-versus-host disease. Key mechanisms include TRAIL secretion, bispecific antibody production, and regulatory T cell induction. Manufacturing scalability, cell persistence, and standardized protocols remain critical hurdles before clinical translation.
Detailed Summary
CAR-T cell therapy has revolutionized hematological oncology, but its limitations — including cytokine release syndrome, neurotoxicity, poor penetration of solid tumors, antigen escape, and high manufacturing costs — have spurred exploration of alternative cell carriers for CAR technology. This comprehensive 2025 review from Army Medical University (Chongqing) systematically examines CAR-MSCs as a compelling next-generation platform, synthesizing preclinical data, engineering strategies, and clinical translation challenges.
MSCs are multipotent stromal cells harvestable from bone marrow, adipose tissue, and umbilical cord, with established safety profiles across more than 1,300 global clinical trials. Their natural properties include tumor tropism, low immunogenicity (low MHC-II and costimulatory molecule expression enabling allogeneic use), secretion of anti-inflammatory cytokines, and capacity to modulate the tumor microenvironment (TME). Grafting CAR constructs onto MSCs is designed to add precision antigen-targeting atop these inherent advantages, creating a dual-modality therapeutic vehicle.
The review traces CAR engineering through five generations. First-generation CARs use a single CD3ζ domain; second-generation add costimulatory domains (CD28 or 4-1BB); third-generation incorporate two costimulatory signals; fourth-generation TRUCKs additionally secrete immunomodulatory cytokines like IL-12; and fifth-generation designs integrate cytokine receptor signaling (e.g., IL-2Rβ/JAK-STAT). Most FDA-approved therapies use second-generation designs. This generational framework is now being applied to MSC engineering.
In preclinical oncology models, CAR-MSCs have demonstrated meaningful antitumor activity via several mechanisms: secretion of TRAIL (TNF-related apoptosis-inducing ligand) to kill tumor cells, production of bispecific antibodies that bridge MSCs to tumor antigens, and induction of regulatory T cells to reshape immunosuppressive TMEs. Specific cancers studied include glioblastoma, Ewing sarcoma, acute myeloid leukemia, and lung cancer. For immune diseases, CAR-MSCs show promise in graft-versus-host disease by leveraging MSCs' Treg-induction and immunosuppressive secretome.
Despite these encouraging results, substantial obstacles remain. Manufacturing scalability is limited by MSC heterogeneity across tissue sources and donor variability. Cell persistence in vivo is often short, reducing sustained therapeutic effect. Gene delivery methods — predominantly viral vectors — raise safety and regulatory concerns, prompting interest in nonviral alternatives. The review advocates for metabolic engineering, senescence-resistant MSC clones, microenvironment-responsive CAR activation, and standardized good manufacturing practice (GMP) workflows with rigorous quality control as priority development areas. No clinical trials of CAR-MSCs have been reported yet, meaning all efficacy data remain preclinical. Interdisciplinary collaboration spanning cell biology, bioengineering, and clinical oncology will be essential for translating CAR-MSCs from bench to bedside.
Key Findings
- CAR-MSCs combine CAR-directed tumor antigen targeting with MSCs' natural tumor homing and immunomodulation in a single cell platform.
- Preclinical models show CAR-MSC activity against glioblastoma, Ewing sarcoma, AML, and lung cancer via TRAIL secretion and bispecific antibodies.
- CAR-MSCs show potential in graft-versus-host disease through regulatory T cell induction and anti-inflammatory cytokine secretion.
- Low immunogenicity of MSCs supports allogeneic 'off-the-shelf' manufacturing, a major advantage over autologous CAR-T cell production.
- Key translation barriers include MSC heterogeneity, poor in vivo persistence, viral vector safety concerns, and absence of standardized manufacturing protocols.
Methodology
This is a comprehensive narrative review synthesizing published preclinical and clinical literature on CAR engineering generations and CAR-MSC applications in oncology and immune diseases. No original experimental data are presented; conclusions are drawn from analysis of preclinical models and clinical trial data for MSC-based therapies. The review was funded by the National Natural Science Foundation of China and several institutional grants.
Study Limitations
All CAR-MSC efficacy data are from preclinical models with no completed clinical trials reported, limiting direct translation of findings. MSC heterogeneity across tissue sources and donors introduces significant variability in therapeutic potency and manufacturability. Cell persistence in vivo remains short, and long-term safety of genetically modified MSCs has not been established in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: